← Leaderboards
James H Stein
University Of Wisconsin Madison
$15,359,061
Attributed
$29,444,074
Total exposure
14
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.1M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$29,603,773 · 15
By mechanism
R01$28,170,027 · 5
K23$680,458 · 1
S10$481,696 · 6
R21$255,789 · 1
M01$15,803 · 2
Top collaborators
- Timothy B Baker10 shared
- Michael C Fiore6 shared
- Judith S. Currier5 shared
- Priscilla Y. Hsue4 shared
Most similar at University Of Wisconsin Madison
Same institution · by research overlap
- Michael C Fiore$34,414,854
- Lyn Y Abramson$5,201,387
- Douglas E Jorenby$2,967,109
- Robert F Lemanske$29,535,752
- Charles R Hutchinson$2,326,474
Others in their field
Top investigators on “Cardiovascular Diseases”
- Chanza Baytop · Westat, Inc.$271,217,917
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$145,558,149
- Judith S. Currier · University Of California Los Angeles$143,001,230
- David M Nathan · Massachusetts Institute Of Technology$141,671,512
- John M Lachin · George Washington University$139,991,329
- Judith S Hochman · New York University School Of Medicine$112,514,057
Research focus
Cardiovascular DiseasesInflammationCardiovascular SystemMediatingAtherosclerosisBrachial ArteryBaseRisk FactorsChronicEventFunctional DisorderCardiovascular Disorder RiskParticipantAffectLung DiseasesNational Heart, Lung, And Blood InstituteEnrollmentInsightInvestigationRandomized Clinical TrialsFutureProtease InhibitorRandomizedEffectiveness
Grant awards (42)
Longitudinal Effects of E-cigarette Use on Cardiovascular and Pulmonary Health$1,287,821
R01 · FY2025 · HL
Longitudinal Effects of E-cigarette Use on Cardiovascular and Pulmonary Health$1,257,395
R01 · FY2024 · HL
E-Cigarette Effects ON Markers of Cardiovascular AND Pulmonary Disease Risk$456,420
R01 · FY2021 · HL · contact PI
Enhancing the Effectiveness of Varenicline Based Smoking Cessation Treatment$1,585,903
R01 · FY2020 · HL
E-Cigarette Effects ON Markers of Cardiovascular AND Pulmonary Disease Risk$458,894
R01 · FY2020 · HL · contact PI
Effects of HIV Infection and HIV Disease Measures on Arterial Function$121,245
R21 · FY2020 · HL · contact PI
Enhancing the Effectiveness of Varenicline Based Smoking Cessation Treatment$1,760,657
R01 · FY2019 · HL
E-Cigarette Effects ON Markers of Cardiovascular AND Pulmonary Disease Risk$458,914
R01 · FY2019 · HL · contact PI
Effects of HIV Infection and HIV Disease Measures on Arterial Function$134,544
R21 · FY2019 · HL · contact PI
Enhancing the Effectiveness of Varenicline Based Smoking Cessation Treatment$1,946,705
R01 · FY2018 · HL
E-Cigarette Effects ON Markers of Cardiovascular AND Pulmonary Disease Risk$458,998
R01 · FY2018 · HL · contact PI
Enhancing the Effectiveness of Varenicline Based Smoking Cessation Treatment$1,734,445
R01 · FY2017 · HL
A Comparative Effectiveness & Long-term Health Study in Wisconsin Smokers$2,013,059
R01 · FY2016 · HL
Effect of low dose methotrexate on endothelial function and inflammation in HIV$305,126
R01 · FY2016 · HL
A Comparative Effectiveness & Long-term Health Study in Wisconsin Smokers$2,073,551
R01 · FY2015 · HL
A Comparative Effectiveness & Long-term Health Study in Wisconsin Smokers$2,079,714
R01 · FY2014 · HL
Effect of low dose methotrexate on endothelial function and inflammation in HIV$634,295
R01 · FY2014 · HL
A Comparative Effectiveness & Long-term Health Study in Wisconsin Smokers$1,925,025
R01 · FY2013 · HL
Effect of low dose methotrexate on endothelial function and inflammation in HIV$617,919
R01 · FY2013 · HL
A Comparative Effectiveness & Long-term Health Study in Wisconsin Smokers$368,069
R01 · FY2013 · HL
Siemens S2000 Cardiovascular Ultrasound System$162,298
S10 · FY2013 · OD · contact PI
Prospective Evaluation of Antiviral Therapy and Cardiac Health$679,219
R01 · FY2012 · HL
Effect of low dose methotrexate on endothelial function and inflammation in HIV$657,753
R01 · FY2012 · HL
A Comparative Effectiveness & Long-term Health Study in Wisconsin Smokers$2,059,311
R01 · FY2011 · HL
Prospective Evaluation of Antiviral Therapy and Cardiac Health$801,848
R01 · FY2011 · HL
Prospective Evaluation of Antiviral Therapy and Cardiac Health$820,964
R01 · FY2010 · HL
Prospective Evaluation of Antiviral Therapy and Cardiac Health$859,156
R01 · FY2009 · HL
Prospective Evaluation of Antiviral Therapy and Cardiac Health$868,866
R01 · FY2008 · HL
EVALUATION OF HYPERCAPNIA-INDUCED CHANGES IN CFV BY TTDE IN HEALTHY SUBJECTS$7,137
M01 · FY2006 · RR · contact PI
Siemens Acuson Sequoia Ultrasound Machine$159,699
S10 · FY2005 · RR
MENTORED PATIENT-ORIENTED RESEARCH CAREER DEVELOPMENT AW$136,348
K23 · FY2005 · RR
SIEMENS ACUSON SEQUOIA ULTRASOUND MACHINE: CVD$63,880
S10 · FY2005 · RR
SIEMENS ACUSON SEQUOIA ULTRASOUND MACHINE: SLEEP DISORDER$63,879
S10 · FY2005 · RR
SIEMENS ACUSON SEQUOIA ULTRASOUND MACHINE: AGING$15,970
S10 · FY2005 · RR
SIEMENS ACUSON SEQUOIA ULTRASOUND MACHINE: HIV$15,970
S10 · FY2005 · RR
MENTORED PATIENT-ORIENTED RESEARCH CAREER DEVELOPMENT AW$136,183
K23 · FY2004 · RR
ASSOCIATION BETWEEN USE OF PROTEASE INHIBITORS &ENDOTHELIAL DYSFUNCTION IN HIV$8,666
M01 · FY2004 · RR
MENTORED PATIENT-ORIENTED RESEARCH CAREER DEVELOPMENT AW$136,348
K23 · FY2003 · RR
MENTORED PATIENT-ORIENTED RESEARCH CAREER DEVELOPMENT AW$136,347
K23 · FY2002 · RR
HIV PROTEASE INHIBITORS AND ATHEROSCLEROSIS$135,232
K23 · FY2001 · RR
PROTEASE INHIBITORS AND ENDOTHELIAL DYSFUNCTION IN PTS W HIV$0
M01 · FY2000 · RR
PROTEASE INHIBITORS AND ENDOTHELIAL DYSFUNCTION IN PTS W HIV$0
M01 · FY2000 · RR